HOUSTON , Aug. 5, 2024 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX ) ("Moleculin" or the "Company"), Phase 3 clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced it will host a corporate update webcast presentation on Tuesday, August 6, 2024 at 8:30 AM ET to discuss its recently announced plans to advance Annamycin in combination with Cytarabine (also known as "Ara-C" and for which the combination of Annamycin and Ara-C is referred to as "AnnAraC") to a Phase 3 pivotal trial for the treatment of AML patients who are refractory to or relapsed after induction therapy (R/R AML).
This Phase 3 "MIRACLE" trial (derived from M olecul i n R /R AML A nnAraC Cl inical E valuation) will be a global trial, including sites in the US. For the webcast presentation , Walter Klemp , Chairman and Chief Executive Officer, and Dr. Paul Waymack , Senior Chief Medical Officer of Moleculin will be joined by Michael Andreeff , MD, PhD, Professor of Medicine, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center.
Interested participants and investors may access the webcast presentation via conference call by dialing (877) 407-0832 (domestic) or (201) 689-8433 (international) and referencing the Moleculin Biotech Conference Call or by clicking here . The live audio webcast will be accessible on the Events page of the Investors section of the Moleculin webs.
